Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - Dealing with unbalanced designs

被引:16
|
作者
Ogungbenro, Kayode
Gueorguieva, Ivelina
Majid, Oneeb
Graham, Gordon
Aarons, Leon
机构
[1] Univ Manchester, Ctr Appl Pharmacokinet Res, Manchester M13 9PL, Lancs, England
[2] Lilly Res Ctr, Global PK PD, Windlesham GU20 6PH, Surrey, England
[3] Pfizer Ltd, Sandwich CT13 9NJ, Kent, England
[4] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England
关键词
pharmacokinetics; pharmacodynamics; D-optimality; optimal design; multiresponse; nonlinear; fixed effects; mixed effects;
D O I
10.1007/s10928-006-9048-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This paper addresses the problem of determining D-optimal designs for multiresponse pharmacokinetic-pharmacodynanfic (PKPD) experiments where data on each response variable can be collected at different times. Most previous multiresponse model optimal design applications have considered the case where all response variables are measured at the same time points. However in practice it may not be possible to have all responses measured at the same sampling times. We propose an optimal design method to take into account the unbalanced nature of the problem. The method developed was applied to a PKPD problem that involved describing the time course of drug plasma concentrations, heart rate and mean arterial blood pressure for both a fixed effects and mixed effects regression model. Additionally a simulation study was carried out in NONMEM for one such population optimal design problem.
引用
收藏
页码:313 / 331
页数:19
相关论文
共 50 条
  • [41] Constructing optimal designs for fitting pharmacokinetic models
    Jones, B
    Wang, J
    [J]. STATISTICS AND COMPUTING, 1999, 9 (03) : 209 - 218
  • [42] Adequate Design of Pharmacokinetic-Pharmacodynamic Studies Will Help Optimize Tuberculosis Treatment for the Future
    Sturkenboom, Marieke G. G.
    Akkerman, Onno W.
    Bolhuis, Mathieu S.
    de Lange, Wiel C. M.
    van der Werf, Tjip S.
    Alffenaar, Jan-Willem C.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (04) : 2474 - 2474
  • [43] Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies
    Roberts, Jessica K.
    Stockmann, Chris
    Balch, Alfred
    Yu, Tian
    Ward, Robert M.
    Spigarelli, Michael G.
    Sherwin, Catherine M. T.
    [J]. PEDIATRIC ANESTHESIA, 2015, 25 (03) : 222 - 230
  • [44] Optimal parametric design with applications to pharmacokinetic and pharmacodynamic trials
    Wang, Jixian
    [J]. JOURNAL OF APPLIED STATISTICS, 2006, 33 (08) : 837 - 852
  • [45] Optimization of chemotherapy and immunotherapy: In silico analysis using pharmacokinetic-pharmacodynamic and tumor growth models
    Kiran, Kanchi Lakshmi
    Lakshminarayanan, S.
    [J]. JOURNAL OF PROCESS CONTROL, 2013, 23 (03) : 396 - 403
  • [46] UNDERSTANDING THE DOSE-EFFECT RELATIONSHIP - CLINICAL-APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELS
    HOLFORD, NHG
    SHEINER, LB
    [J]. CLINICAL PHARMACOKINETICS, 1981, 6 (06) : 429 - 453
  • [47] Evaluation of different pharmacokinetic-pharmacodynamic models for tumor growth delay prediction after chemotherapy
    Terterov, I. N.
    Chubenko, V.
    Knyazev, N. A.
    Klimenko, V.
    Bogdanov, A. A.
    Moiseyenko, V. M.
    Bogdanov, A. A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S366 - S367
  • [48] On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships
    Christopher W. McAleer
    Amy Pointon
    Christopher J. Long
    Rocky L. Brighton
    Benjamin D. Wilkin
    L. Richard Bridges
    Narasimham Narasimhan Sriram
    Kristin Fabre
    Robin McDougall
    Victorine P. Muse
    Jerome T. Mettetal
    Abhishek Srivastava
    Dominic Williams
    Mark T. Schnepper
    Jeff L. Roles
    Michael L. Shuler
    James J. Hickman
    Lorna Ewart
    [J]. Scientific Reports, 9
  • [49] On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships
    McAleer, Christopher W.
    Pointon, Amy
    Long, Christopher J.
    Brighton, Rocky L.
    Wilkin, Benjamin D.
    Bridges, L. Richard
    Sriram, Narasimham Narasimhan
    Fabre, Kristin
    McDougall, Robin
    Muse, Victorine P.
    Mettetal, Jerome T.
    Srivastava, Abhishek
    Williams, Dominic
    Schnepper, Mark T.
    Roles, Jeff L.
    Shuler, Michael L.
    Hickman, James J.
    Ewart, Lorna
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [50] Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation
    Antonio Lepel, Jose
    Garcia-Cabrera, Emilio
    Victoria Gil-Navarro, Maria
    Aznar, Javier
    [J]. REVISTA ESPANOLA DE QUIMIOTERAPIA, 2012, 25 (02) : 134 - 138